| Literature DB >> 29963174 |
Yi Sun1, Hongling Zou2, Liu Yang1, Mengting Zhou1, Xiaoling Shi1, Yarui Yang3, Wenjun Chen1, Yingqi Zhao1, Jie Mo1, Yuanming Lu1.
Abstract
Liver cancer is one of the leading causes of cancer associated mortality, particularly in eastern Asia. Autophagy serves an important role in carcinogenesis. Previous studies have reported that TRAP1 is a novel and efficient therapeutic target in various tumors. However, the associations between autophagy and TRAP1 is not clear. In the present study, autophagy activity and TRAP1 expression were examined in 4 different liver cancer cell lines (HepG2, Hep3B2.1-7, Sk-hep1 and HepG2.2.15) with or without rapamycin induction. The cell autophagy level was validated by monodansylcadaverine fluorescent staining, and the expression levels of Beclin1 and light chain (LC)-3-II/LC3-I. The mRNA and protein expression levels of tumor necrosis factor receptor-associated protein-1 (TRAP-1), Beclin1 and LC3-II/LC3-I were measured by reverse transcription-quantitative polymerase chain reaction, Protein Simple Western and western blot analysis. HepG2 cells, with medium invasive ability, exerted the highest basal level of autophagy and TRAP1 expression. In addition, hepatitis B (HBV) infection in HepG2 cells inhibited autophagy activity and TRAP1 expression. Rapamycin treatment also significantly enhanced autophagy in the 4 liver cancer cell lines and increased TRAP1 expression in HepG2, Hep3B2.1-7 and Sk-hep1 cells. Thus, the cell invasive ability, HBV infection and autophagy induction had different effects on TRAP1 expression, and TRAP1 may be associated with autophagy in liver cancer.Entities:
Keywords: autophagy; hepatitis B; invasive ability; liver cancer; tumor necrosis factor receptor-associated protein-1
Year: 2018 PMID: 29963174 PMCID: PMC6019943 DOI: 10.3892/ol.2018.8774
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1.(A) Cell growth of HepG2, HepG2.2.15, Sk-hep1 and Hep3B2.1–7 cells was examined by cell counting over 5 days. (B) Growth curves of HepG2 cells following treatment with 0, 5, 10 and 15 µmol/l rapamycin.
Figure 2.Protein levels of Beclin1 and LC3-II/LC3-I in 4 liver cancer cell lines were determined by western blot analysis. β-actin was used as an internal control. **P<0.01, as indicated. LC3, light chain 3.
Figure 3.(A) Protein levels of Beclin1 and LC3-II/LC3-I were examined in 4 liver cancer cells treated with 0, 5, 10 and 15 µmol/l rapamycin by western blot analysis. β-actin was used as an internal control. (B) Monodansylcadaverine method was used to detect the cell autophagy of HepG2 cells (magnification, ×400). (C) The WES™ automated capillary-based size sorting system was used to measure the protein level of Beclin and β-actin in HepG2 cells. *P<0.05 and **P<0.01, as indicated. LC3, light chain 3; MW, molecular weight.
Figure 4.(A) Reverse transcription-quantitative polymerase chain reaction was used to detect the TRAP1 mRNA expression levels in Hep3b2.1–7, HepG2, HepG2.2.15 and Sk-hep1 cells. (B) The protein levels of TRAP1 in the 4 liver cancer cell lines were determined by western blot analysis. β-actin was used as an internal control. (C) WES™ automated capillary-based size sorting system was used to measure the protein level of TRAP1 and β-actin in 4 liver cancer cell lines. (D) The protein levels of TRAP1 were examined in 4 liver cancer cells treated with 0, 5, 10 and 15 µmol/l rapamycin by western blot analysis. β-actin was used as an internal control. *P<0.05 and **P<0.01, as indicated. TRAP1, tumor necrosis factor receptor-associated protein-1.